MARKETS
Markets

Arrowhead Pharmaceuticals To Present Data On Plozasiran In Patients With Severe Hypertriglyceridemia At European Society Of Cardiology Congress

Aug 24, 2026 · 07:31 AM ET· updated 46m ago

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it will present important new data at the European Society of Cardiology Congress (ESC) in Munich, Germany.

Share
Why It Matters

Arrowhead is showing doctors new information about a medicine it's testing that could help people with very high fat in their blood. When companies share results at big medical meetings, it's a chance to see if their medicine is working the way they hoped.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.